Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$28.09
$1.42(5.06%)
At close: 4:00 PM EDT
$28.09
$1.42(5.06%)
Day’s Range― - ―
52-Week Range$13.74 - $65.30
Previous CloseN/A
Volume4.79M
Average Volume (3M)15.98M
Market Cap
$6.68B
Enterprise Value$8.74K
Total Cash (Recent Filing)$841.05M
Total Debt (Recent Filing)$1.55B
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Nov 09, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding224,935,790
10 Day Avg. Volume14,448,064
30 Day Avg. Volume15,981,831
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.75Price Target Upside20.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$2.93B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Subscriber GrowthRapid revenue expansion and a nearly 3 million subscriber base improve platform scale, recurring-plan potential and cross-sell opportunities. Continued customer additions can support durable growth by spreading technology, clinical and fulfillment costs across a larger base.
International Platform ExpansionThe Eucalyptus acquisition adds local regulatory expertise, established regional operations and access to multiple international markets. This broadens Hims & Hers’ addressable customer base and creates a platform for localized care offerings and longer-term international operating leverage.
Positive Underlying Cash Generation And AI EfficiencyPositive trailing cash generation despite a TTM accounting loss provides liquidity to fund growth, while AI adoption could lower service costs and improve engagement. Together, these factors support a more scalable model if efficiency gains persist as membership expands.
Bears Say
Materially Higher LeverageDebt has increased sharply from minimal historical levels, leaving the company more exposed to refinancing, covenant and execution risks. High leverage reduces financial flexibility and could constrain investment or increase funding pressure if profitability remains inconsistent.
Margin Compression And Renewed GAAP LossesThe shift toward branded weight-loss products and international revenue is structurally lowering gross margins, while the return to losses weakens earnings quality. Sustained mix pressure could limit operating leverage and make the path from growth to durable profitability less predictable.
Regulatory And Legal UncertaintyThe FTC action may generate legal costs, operational requirements or restrictions on customer practices, while FDA rulemaking could delay peptide launches. These uncertainties may limit product expansion and create compliance costs in strategically important growth categories.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $13.74 and its highest was $65.30 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $6.68B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 82 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.32.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is 0.07.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 224,935,790 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.966%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.75 (20.15% Upside)
$33.75 (20.15% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 74%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $342.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-47.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.27%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$33.75
▲(20.15% Upside)
Technical Analysis
Ownership Overview
5.28% Insiders
14.65% Mutual Funds
11.77% Other Institutional Investors
47.65% Public Companies and Individual Investors